Patent Baristas

Earlier, I asked if anyone could provide insight into the U.S. Patent Office’s proposed rules to limit the number of continuing, CIP and RCE applications that can be filed by patent applicants. Mr. Roy Marsh, a European Patent Attorney in Munich with Hoffmann Eitle, writes: I surmise that the USPTO is envious of EPO success […]

News of patent anarchy are ringing throughout the land citing the troubles with the U.S. Patent and Trademark Office (USPTO) both for its long processing times and cries that it issues too many “unworthy” patents, which fall into the hands of the evil Patent Trolls who hold up legitimate businesses for ransom. While the troll […]

The USPTO has proposed rules to limit the number of continuing, CIP and RCE applications that can be filed by patent applicants. See here for the notice. Why have continuations become the current whipping boy for the Patent Office? The Notices states that “current practice allows an applicant to generate an unlimited string of continued […]

“What To Do About Bad Patents” under Briefly Noted by Profs. Lemley, Lichtman and Sampat (the Profs.) bemoans today’s patents, and then asks whether past problems provide a formula for new solutions. In their equation, opposing values are placed on either side of the equal sign. (If not for our talent of scaling justice, and […]

Evan Schaeffer’s Legal Underground hosts Blawg Review #38 this week with a timely theme: resolutions. His list of Ten New Year’s Resolutions for Bloggers was born from his recent talk at BlawgThink 2005 in Chicago. We most appreciated Resolution 1: Mix It Up. This is one we want to strive for in 2006. Even though […]

In the U.S. Court of Appeals for the Federal Circuit case Perricone v. Medicis Pharm. Corp. (case 05-1022, 05-1023), decided December 20, 2005, summary judgment of invalidity and non-infringement on claims in a patent infringement case involving methods of treating sunburns and skin damage was reversed because the district court erred in its anticipation analysis […]

Forbes ran an interesting article about Genentech that shows how it pursues a different path than traditional Big Pharma companies like Pfizer and Merck, which market drugs to the masses. Genentech takes a very different approach by foregoing mass-market medicines in favor of drugs specific for severe diseases even if that limits the market potential. […]

In some other news of kudos for out site, TopTenSources has selected Patent Baristas to be a featured Top 10 Source site. Top 10 Sources publishes a daily “Top 10” site of the best newsfeeds on the Internet. Their editors pick a topic then find the ten best sources on the Net on that topic […]